Register for our free email digests:
Simcere Pharmaceutical Group
http://en.simcere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Simcere Pharmaceutical Group
Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Vaccines
- Other Names / Subsidiaries
-
- Jilin Boda Pharmaceutical Co., Ltd.
- ChinaVax
- Master Luck Corporation Limited
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
- Jiangsu Yanshen Biological Technology Stock Co., Ltd.
- Nanjing Tung Chit Pharmaceutical Co., Ltd.
- Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
- Wuhu Zhong Ren Pharmaceutical Co. Ltd.
- Xiangao Investment Company Ltd.
- Yantai Medgenn Co. Ltd.
- Jiangsu Simcere Pharmaceutical Co., Ltd.